New Triple-Drug attack on Tough-to-Treat leukemia shows early promise
NCT ID NCT06611839
Summary
This study is testing a new combination of three drugs (venetoclax, ivosidenib, and azacitidine) for adults with a specific genetic form of acute myeloid leukemia (AML) who are eligible for intensive chemotherapy. The main goals are to find the safest dose of this triple-drug regimen and to see how well it works at controlling the leukemia over the long term. Researchers will also track if the treatment can get rid of nearly all cancer cells and how that affects decisions about future treatments like stem cell transplants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.